Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression - sprookjes - yvandenbroek - TriplyDB

Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression

Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression

http://www.wikidata.org/entity/Q28299091

about

Cancer-associated fibroblasts in hepatocellular carcinoma Interaction between circulating cancer cells and platelets: clinical implication Harnessing the genome for characterization of G-protein coupled receptors in cancer pathogenesis Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade Exocrine pancreatic carcinogenesis and autotaxin expression Higher LPA2 and LPA6 mRNA Levels in Hepatocellular Carcinoma Are Associated with Poorer Differentiation, Microvascular Invasion and Earlier Recurrence with Higher Serum Autotaxin Levels Loss of lysophosphatidic acid receptor-3 suppresses cell migration activity of human sarcoma cells.Role of LPAR3, PKC and EGFR in LPA-induced cell migration in oral squamous carcinoma cells.cPLA2α mediates TGF-β-induced epithelial-mesenchymal transition in breast cancer through PI3k/Akt signaling.Expression of lysophosphatidic acid, autotaxin and acylglycerol kinase as biomarkers in diabetic retinopathy.Fibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs).Expression of bioactive lysophospholipids and processing enzymes in the vitreous from patients with proliferative diabetic retinopathy Autotaxin and LPA1 and LPA5 receptors exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis Massively parallel sequencing reveals an accumulation of de novo mutations and an activating mutation of LPAR1 in a patient with metastatic neuroblastoma Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.Small lipidated anti-obesity compounds derived from neuromedin U.c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study.Association between Promoter Hypomethylation and Overexpression of Autotaxin with Outcome Parameters in Biliary Atresia Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin.Expressions of lysophosphatidic acid receptors in the development of human ovarian carcinoma.Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis.Expression and function of lysophosphatidic acid receptors (LPARs) 1 and 3 in human hepatic cancer progenitor cells The gep proto-oncogene Gα13 mediates lysophosphatidic acid-mediated migration of pancreatic cancer cells.EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis Ras-association domain family 10 acts as a novel tumor suppressor through modulating MMP2 in hepatocarcinoma.Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8.IL-1β-induced activation of p38 promotes metastasis in gastric adenocarcinoma via upregulation of AP-1/c-fos, MMP2 and MMP9 Cholera toxin inhibits human hepatocarcinoma cell proliferation in vitro via suppressing ATX/LPA axis.Roles of p38 MAPKs in invasion and metastasis.Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays.Diverse effects of LPA receptors on cell motile activities of cancer cells.Lysophosphatidic Acid Promotes Epithelial to Mesenchymal Transition in Ovarian Cancer Cells by Repressing SIRT1.Gene regulatory networking reveals the molecular cue to lysophosphatidic acid-induced metabolic adaptations in ovarian cancer cells Acylglycerol kinase is over-expressed in early-stage cervical squamous cell cancer and predicts poor prognosis.Lysophosphatidic acid induces both EGFR-dependent and EGFR-independent effects on DNA synthesis and migration in pancreatic and colorectal carcinoma cells.Inhibitory effects of lysophosphatidic acid receptor-5 on cellular functions of sarcoma cells.Lysophosphatidic acid receptor-5 negatively regulates cell motile and invasive activities of human sarcoma cell lines.

P2860

Q26738536-2D75F253-3B0E-49CE-AFD4-243B00A7E5B5 Q26778920-DA4980ED-6C9B-47B6-A5D6-8AF03932E9EE Q26861766-5BA2EF4D-A821-46F0-8493-114F3B058BE0 Q27015257-62675D48-4E33-4D5C-A0E6-A6E95A20D097 Q28288148-95E12517-4F03-4B2A-AF58-AC60B6984207 Q28482954-D794F426-DC3B-4AD0-BEDE-F1FBA6293BDF Q29048613-7B8D6DAC-E40C-40A0-AB29-6B96446E44FE Q30009974-3D4EF4D5-5FBE-46DD-A7BF-9E6B1C65BC05 Q33786333-76CF8D87-C0A5-4ACD-98DF-D31AED564DC5 Q33815876-D066DEDD-715C-44C6-A1F7-BA0FAB533717 Q34292377-7731225E-1BD3-478A-A8E9-2B734931D45E Q34309876-2C07CBE4-8A5F-4993-9090-A55CD36328F4 Q34941725-9F700ED1-6859-4CB9-9EED-9593FC1280B4 Q34980426-1FF19640-D2B6-4EE8-B10F-C00682684D28 Q35023369-7DD81E55-EBBC-43DD-A1C4-24E9C0BE2727 Q35551835-1D4AFFC3-4E58-44A1-B09D-2EB265859808 Q35708420-E911240B-CAC6-4FA3-94D0-6FEBA3DA8D1B Q35756057-F1E30633-97DD-475A-BAE5-68D0E97F88CE Q36181402-516C71BC-4ECA-4EB6-BB12-9D0E3AD81CA1 Q36239556-817CA04A-CF53-4A65-B923-7DCFC42930FB Q36399256-B5F054CD-F02F-42C7-A5CD-DF19B84C609E Q36405959-817BDDF4-90C4-42E2-BABE-8551D595063E Q36411668-328B31FE-9D3E-43CA-9FA5-F0BC85CC3D3D Q36664243-0F995F6E-F6A6-4E90-B3A6-7D83A0C06E2B Q36771993-76D35C96-D7B5-47FD-ABE0-88442E6E0A5E Q36941344-2C51D058-1229-442A-B46B-FA897E446285 Q36950009-4F617EC3-43FD-43C9-B79D-1196FE2FE1DB Q37096218-5EC27D72-3EC0-4176-BFAC-284CBB249008 Q37368282-4A0F08BC-95A1-41A1-B0F9-BD2565AB3695 Q37607600-1986A654-7904-4173-A5DE-C2F663C72ED8 Q37728367-72158723-767A-4D86-8F89-05AC0C530B00 Q37977166-44108BD1-C533-49F3-87B2-780E05365943 Q38101074-79677241-DCD8-4C1C-AA99-97BEF8CEA8C1 Q38181530-C5417160-7122-4278-867D-CF748AA756D3 Q38715858-7A1201CC-E767-4B66-A530-57F80659557F Q38753397-0E4AD2B6-2C09-4A5B-8F2C-BCB2A31721AC Q38812093-57E6B006-60EC-4674-A822-76B5F8C30E2A Q38834081-7993698A-1FD3-4FF3-BCF6-BFAE33552F35 Q38998311-49208B7E-9860-4CB8-A65E-C2FE071328F3 Q39010837-F76C88FA-DAFD-46A7-9736-948CF2312039

P2860

Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression

http://www.wikidata.org/entity/Q28299091

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Lysophosphatidic acid augments ...... receptor and MMP-9 expression

@ast

Lysophosphatidic acid augments ...... receptor and MMP-9 expression

@en

Lysophosphatidic acid augments ...... receptor and MMP-9 expression

@nl

type

label

Lysophosphatidic acid augments ...... receptor and MMP-9 expression

@ast

Lysophosphatidic acid augments ...... receptor and MMP-9 expression

@en

Lysophosphatidic acid augments ...... receptor and MMP-9 expression

@nl

prefLabel

Lysophosphatidic acid augments ...... receptor and MMP-9 expression

@ast

Lysophosphatidic acid augments ...... receptor and MMP-9 expression

@en

Lysophosphatidic acid augments ...... receptor and MMP-9 expression

@nl

P1433

Q28299091-65AC2526-4870-473D-86E1-80433C53A97E

P1476

Q28299091-5905C12E-F35B-49FA-98D4-872AF61DCDB1

P2093

Q28299091-1030CAB5-B685-4318-85AC-E765EDC70D54

Q28299091-1CD8A637-DC4D-459E-8079-AC318FA95FA2

Q28299091-314D6C7B-D18D-4FAB-AA9F-7C45A47206C0

Q28299091-727B2E4A-E8BA-400A-96B8-3C518CD8A5E9

Q28299091-8BD1F290-E862-4DE2-B516-B3D9A86179A3

Q28299091-905EDE7F-3C9B-4B9C-AC29-DA0A283EB1BA

Q28299091-AEE819F5-E342-4D18-AEFB-A9542B2161C7

Q28299091-BAB8A546-9389-4407-B67C-A1EBF7936F7B

Q28299091-C1143527-9941-4B1D-84DA-07A971E31BDD

Q28299091-E8728DEA-E040-4A99-B897-464EECE1D6BA

P2860

Q28299091-037F37E2-FEFF-4540-8628-52CFC7227997

Q28299091-05DD50C7-70AC-4BCC-B82B-40FA592CB135

Q28299091-068CB1DB-64C7-4AA0-A7F9-8C2683857A1D

Q28299091-06A91E45-0194-484A-A57F-8D6C6705C504

Q28299091-26A11130-EA54-4DBA-9317-29F5F614FBF3

Q28299091-2A3ADFB8-8152-4B75-97C9-D2EEB9BA8E1B

Q28299091-2C766407-00C9-4823-A8A2-88BD852A71E8

Q28299091-3785F757-6F9A-4440-B24C-63F972802948

Q28299091-40905579-1AD0-4136-9C5E-4661055368B2

Q28299091-663C828D-2D7C-43C8-8886-F62E477D788D

P2888

Q28299091-97A16482-E1AC-4B0A-AA80-074B49347FE2

P304

Q28299091-13EFB981-B6AB-43AB-90CF-45DEACFC8EA5

P31

Q28299091-8F1103F6-DCD8-4206-90F3-62AC6DC66F05

P3181

Q28299091-5F75AE5F-D8AD-42C2-AB8E-5BD4234F6C65

P356

Q28299091-AC25A51C-9EFF-4460-B06E-24992AD09D06

P407

Q28299091-670E52CE-A287-4506-B463-6A425C6AB8D1

P433

Q28299091-08A0376C-4D1A-4967-92FE-C0D10134B9F2

P478

Q28299091-0DF687A4-73E3-404F-A77A-B2BA5E3C769B

P577

Q28299091-A7CEA375-D76A-4BD7-9E98-CA70BCA94BB8

P5875

Q28299091-35FF9366-7341-42C4-9552-9802648DD8CE

P6179

Q28299091-2856E539-1C67-47B2-874D-288A5704EB50

P698

Q28299091-2912575C-8D4A-4D57-83DF-C2725B5BB8E6

P3181

P356

P1433

P1476

Lysophosphatidic acid augments ...... receptor and MMP-9 expression

@en

P2093

C G Park

http://www.w3.org/2001/XMLSchema#string

G B Mills

http://www.w3.org/2001/XMLSchema#string

H Y Lee

http://www.w3.org/2001/XMLSchema#string

J Kang

http://www.w3.org/2001/XMLSchema#string

J Lee

http://www.w3.org/2001/XMLSchema#string

J M Kim

http://www.w3.org/2001/XMLSchema#string

J W Han

http://www.w3.org/2001/XMLSchema#string

J-S Lee

http://www.w3.org/2001/XMLSchema#string

K J Jeong

http://www.w3.org/2001/XMLSchema#string

N Panupinthu

http://www.w3.org/2001/XMLSchema#string

P2860

Agonist-induced endocytosis of lysophosphatidic acid-coupled LPA1/EDG-2 receptors via a dynamin2- and Rab5-dependent pathway

The emerging role of lysophosphatidic acid in cancer

Development of matrix metalloproteinase inhibitors in cancer therapy.

Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma.

Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases.

Estimating the world cancer burden: Globocan 2000.

Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction.

The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases

Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.

Sharpening the edges of understanding the structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation.

P2888

P304

1351-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1290405

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/ONC.2010.517

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49631063

http://www.w3.org/2001/XMLSchema#string

P6179

1026583812

http://www.w3.org/2001/XMLSchema#string

P698

21102517

http://www.w3.org/2001/XMLSchema#string